These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 21715364

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
    Ioka T, Komatsu Y, Mizuno N, Tsuji A, Ohkawa S, Tanaka M, Iguchi H, Ishiguro A, Kitano M, Satoh T, Yamaguchi T, Takeda K, Kida M, Eguchi K, Ito T, Munakata M, Itoi T, Furuse J, Hamada C, Sakata Y.
    Br J Cancer; 2017 Feb 14; 116(4):464-471. PubMed ID: 28081543
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
    Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, Hanada K, Kimura Y, Maetani I, Okabe Y, Tani M, Ikeda T, Hijioka S, Watanabe R, Ohoka S, Hirose Y, Suyama M, Egawa N, Sofuni A, Ikari T, Nakajima T.
    Cancer Chemother Pharmacol; 2012 May 14; 69(5):1197-204. PubMed ID: 22249272
    [Abstract] [Full Text] [Related]

  • 6. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E.
    Cancer Chemother Pharmacol; 2009 Jan 14; 63(2):313-9. PubMed ID: 18398614
    [Abstract] [Full Text] [Related]

  • 7. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T, Ueno M, Ueno H, Park JO, Chang HM, Sasahira N, Kanai M, Chung IJ, Ikeda M, Nakamori S, Mizuno N, Omuro Y, Yamaguchi T, Hara H, Sugimori K, Furuse J, Maguchi H, Furukawa M, Fukuzawa K, Kim JS, Yukisawa S, Takeuchi M, Okusaka T, Boku N, Hyodo I.
    Eur J Cancer; 2019 Jan 14; 106():78-88. PubMed ID: 30471651
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
    Kim HS, Kim HY, Zang DY, Oh HS, Jeon JY, Cho JW, Park CK, Kim JH, Kim MJ, Ha HI, Kim JH, Han B, Song H, Kwon JH, Choi DR, Jung JY.
    Cancer Chemother Pharmacol; 2015 Apr 14; 75(4):711-8. PubMed ID: 25630414
    [Abstract] [Full Text] [Related]

  • 9. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
    Ohkawa S, Okusaka T, Isayama H, Fukutomi A, Yamaguchi K, Ikeda M, Funakoshi A, Nagase M, Hamamoto Y, Nakamori S, Tsuchiya Y, Baba H, Ishii H, Omuro Y, Sho M, Matsumoto S, Yamada N, Yanagimoto H, Unno M, Ichikawa Y, Takahashi S, Watanabe G, Wakabayashi G, Egawa N, Tsuda M, Hosotani R, Hamada C, Hyodo I.
    Br J Cancer; 2015 Apr 28; 112(9):1428-34. PubMed ID: 25880004
    [Abstract] [Full Text] [Related]

  • 10. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
    Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS, Shan YS, Chen LT.
    Eur J Cancer; 2020 Jan 28; 124():123-130. PubMed ID: 31765987
    [Abstract] [Full Text] [Related]

  • 11. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
    Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, Furuse J, Ishii H, Nagase M, Nakachi K.
    Oncology; 2005 Jan 28; 69(5):421-7. PubMed ID: 16319514
    [Abstract] [Full Text] [Related]

  • 12. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
    Saito K, Isayama H, Nakai Y, Takahara N, Ishigaki K, Takeda T, Hakuta R, Saito T, Uchino R, Kishikawa T, Hamada T, Mizuno S, Sasaki T, Kogure H, Matsubara S, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K.
    Invest New Drugs; 2019 Apr 28; 37(2):338-344. PubMed ID: 30411217
    [Abstract] [Full Text] [Related]

  • 13. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
    Kim MK, Lee KH, Jang BI, Kim TN, Eun JR, Bae SH, Ryoo HM, Lee SA, Hyun MS.
    Jpn J Clin Oncol; 2009 Jan 28; 39(1):49-53. PubMed ID: 19060295
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
    Hamada C, Okusaka T, Ikari T, Isayama H, Furuse J, Ishii H, Nakai Y, Imai S, Okamura S.
    Br J Cancer; 2017 Jun 06; 116(12):1544-1550. PubMed ID: 28472821
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer.
    Cheng YJ, Meng CT, Shao YJ, Li NN, Zhou N, Yan XY, Gao X, Zhou JF, Bai CM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug 20; 39(4):562-567. PubMed ID: 28877836
    [Abstract] [Full Text] [Related]

  • 16. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
    Kanai M, Yoshimura K, Tsumura T, Asada M, Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K, Taura K, Mori Y, Hamada A, Inoue N, Tada S, Yanagihara K, Yazumi S, Osaki Y, Chiba T, Ikai I, Fukushima M, Uemoto S, Hatano E.
    Cancer Chemother Pharmacol; 2011 Jun 20; 67(6):1429-34. PubMed ID: 20811895
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
    Lee GW, Kim HJ, Ju JH, Kim SH, Kim HG, Kim TH, Kim HJ, Jeong CY, Kang JH.
    Cancer Chemother Pharmacol; 2009 Sep 20; 64(4):707-13. PubMed ID: 19151975
    [Abstract] [Full Text] [Related]

  • 18. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
    Okusaka T, Miyakawa H, Fujii H, Nakamori S, Satoh T, Hamamoto Y, Ito T, Maguchi H, Matsumoto S, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Chen JS, Cheng AL, Sato A, Ohashi Y, Tanaka M, GEST group.
    J Cancer Res Clin Oncol; 2017 Jun 20; 143(6):1053-1059. PubMed ID: 28210843
    [Abstract] [Full Text] [Related]

  • 19. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C, Kuang M, Xu W, Zhang X, Chen J, Tang C.
    Jpn J Clin Oncol; 2015 Dec 20; 45(12):1122-30. PubMed ID: 26518328
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
    Nakachi K, Furuse J, Kinoshita T, Kawashima M, Ishii H, Ikeda M, Mitsunaga S, Shimizu S.
    Cancer Chemother Pharmacol; 2010 Aug 20; 66(3):527-34. PubMed ID: 19967537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.